On this episode of BioTech Nation...Dr. James Mackay joins to talk about the progress Crystalys Therapeutics is making in the treatment of gout - a disease that affects more than 13 million people in the United States alone. Dr. Mackay debunks some common misconceptions surrounding the disease, and explains what Crystalys is doing to change the way doctors treat gout going forward. 

You've probably heard of Peptides...but what exactly are they? And how do we know which ones are effective, and safe? Dr. Karsten Eastman, Co-Founder and CEO of Sethera Therapeutics, joins to answer all our questions about Peptides, and to tell us about Sethera's latest efforts to enhance peptides to make new medicines. Their plan: to develop a drug using enhanced peptides for Triple-Negative Breast Cancer... and they've already received funding.

This week on BioTech Nation, Sameer Sabir, CEO of Brixton Biosciences, shares how their breakthrough injectable cold therapy, Neural Ice, could offer lasting relief for osteoarthritis pain. With a drug-free, nerve-targeting approach currently in clinical trials, this innovation may change how we treat joint pain without pills or repeated steroid injections.

Imagine a world where the toughest wounds heal twice as fast, and patients get their lives back sooner than anyone thought possible. Dr. Ned Swanson, the President and Chief Medical Officer of Polarity Bio, tells us about their approach to healing serious, hard-to-treat skin wounds. In early trials, it's twice as effective as the current treatment for diabetic foot ulcers.

Can you imagine parents expecting a baby, going in for an ultrasound, and finding out that their baby is missing the heart's left ventricle? This week on BioTech Nation, we hear Dr. Joshua Hare, Co-Founder and Chief Scientific Officer of Longeveron, talk about how they are testing the use of stem cells to treat babies born with a serious congenital heart defect.

This week on BioTech Nation, we explore a new approach to cancer treatment that could help patients manage pain without compromising their care. Dr. Lorin Johnson, CSO of Glycyx Therapeutics explains how a new once-daily pill could help patients manage pain without blocking their treatment.

This week on BioTech Nation, Dr. Jeff Stein, President & CEO of Cidara Therapeutics, brings up promising news about a new approach to flu shots.

On this episode of BioTech Nation, Dr. Will Decker and Jay Hartenbach join Moira to talk about Diakonos Oncology's unique approach to cancer immunotherapy, and how a discovery made over two decades ago started it all. Now, with a new drug entering Phase II human trials for Glioblastoma treatment, that discovery could mean a pathway to treating aggressive cancers...

This week on BioTech Nation, Dr. Steve Harr, CEO of Sana Biotechnology, talks about their progress in Type I diabetics, in particular. The New England Journal of Medicine publishes early success with Sana Biotechnology's engineered insulin-producing cells without the need for immunosuppressant drugs.

On this episode of BioTech Nation...The Biotech landscape is ever-evolving - but where are we headed?? Dr. Jeremy Levin, Physician, Bioentrepreneur, and Former Chair of BIO, joins Moira to talk about the future of Biotech from the front lines of the industry - from understanding the global Bioeconomy, to preparing for the next pandemic, and how government policy is impacting innovation. 
His book is, "Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust".